Thanks Doc. I asked Single Stock because he expects a buyout post MHRA approval. I think he cited management age and lack of hiring activity as the key reasons which makes sense. Or maybe I am mixing up names and someone else made this observation.
The way I see it, the management posture tell us one of two things:
1) Buyout post MHRA approval.
2) Partnership with big pharma where they take on sales, marketing, distribution, etc of DCVAX-L for GBM indication and NWBO gets a large upfront payment and some percentage of sales. And then NWBO focuses on new exciting combo trials for other indications with additional influx of capital from big pharma.
Which side are you on?
News 
Market Data 
Discover 
